

Global Noncommunicable Disease Research: Opportunities and Challenges

Lindsay M. Jaacks, PhD; Mohammed K. Ali, MBChB, MSc, MBA; John Bartlett, MD; Gerald S. Bloomfield, MD, MPH; William Checkley, MD; Thomas A. Gaziano, MD, MSc; Douglas C. Heimbürger, MD, MS; Sandeep P. Kishore, MD, PhD; Racquel E. Kohler, PhD, MSPH; Kasia J. Lipska, MD, MHS; Olivia Manders, MA; Christine Ngaruiya, MD, DTM&H; Robert Peck, MD, MS; Melissa Burroughs Pena, MD, MS; David A. Watkins, MD, MPH; Karen R. Siegel, PhD, MPH; and K.M. Venkat Narayan, MD, MSc, MBA

Opportunities for collaboration on global noncommunicable disease (NCD) research across international borders and scientific disciplines are increasingly available, coinciding with globalization of science and an unprecedented interest in global health among U.S. students, clinicians, and early-career investigators (1). However, challenges to developing and funding a global NCD research agenda remain. In September 2014, researchers representing 41 institutions, including universities, government agencies, private companies, journals, and foundations in the United States met to discuss the challenges and identify opportunities for moving forward on a global NCD research agenda. Four action items emerged from this conference.

BUILD BRIDGES BETWEEN COMMUNICABLE DISEASE AND NCD RESEARCH

The conventional dichotomy of communicable diseases and NCDs in global health must be replaced with a more holistic approach to health. Noncommunicable disease researchers and governments could leverage infrastructure and cohorts already established or being developed for communicable disease research (2). Collaborations will naturally emerge in 2 domains: strengthening primary care systems in low-resource settings to manage various common infections and chronic conditions and establishing integrated care models for persons with chronic HIV or AIDS who are also affected by NCDs (3). Collaborative work in the second domain is urgently needed given the rapid increase in life expectancy among persons with HIV internationally after the global distribution of antiretroviral drug treatment (3). Unfortunately, a major challenge for such interdisciplinary projects is that most funding agencies focus on specific conditions. Infrastructure development, clinical research, and public health research are typically funded through different sources, and this further complicates matters.

ENCOURAGE RECIPROCAL EXCHANGES OF HEALTH INNOVATIONS BETWEEN U.S. AND GLOBAL HEALTH

Investments in global NCD research do not need to be a zero-sum game in which investment in global health detracts from U.S. health. Although most global health efforts have focused on implementing evidence-based practices from the developed world in develop-

ing countries, adoption of health care innovations from resource-limited settings (such as use of lay community health workers for primary care delivery and mobile phones to improve patient adherence) in the United States may reduce health care costs and improve patient outcomes (4). In addition, global NCD research findings may be directly applicable to the United States because its population is becoming more ethnically diverse.

BETTER COMMUNICATE THE BENEFITS OF GLOBAL NCD RESEARCH INVESTMENT

Global NCD researchers, the National Institutes of Health (NIH), and other institutions supported by U.S. taxpayers must clearly communicate the benefits to be gained by the United States from engaging in global NCD research (Table). A few of the potential scientific benefits include gaining a greater understanding of the health effects of a wider range of exposures to environmental pollutants, particularly high-dose exposures, and access to large samples from diverse populations for genomic studies and clinical trials. For clinicians, international work offers opportunities to broaden their medical knowledge, refine their physical examination and diagnostic skills, and become more culturally competent (5).

Creating incentives for trainees to work abroad can strengthen their research skills. The 32 U.S. fellows supported by the National Heart, Lung, and Blood Institute's Centers of Excellence program for global NCD research published more than 70 manuscripts, and the 536 fellows supported by the NIH Fogarty International Clinical Research Scholars and Fellows Program published more than 3000 manuscripts (6). This productivity improves the academic breadth and prestige of universities.

Promoting health equity around the globe can improve political stability (7). The U.S. Department of State recognizes this link between global health and U.S. security and promotes shared responsibility for improving health internationally. The President's Emergency Plan for AIDS Relief exemplifies this soft political influence through health diplomacy. Policymakers should respond to requests from low- and middle-income country governments, which are beginning to focus on NCDs.

Table. Summary of Benefits to U.S. Science, Academic Institutions, Investigators, and Others From Engaging in Global Noncommunicable Disease Research

Science	Academic Institutions	Investigators	Others
Reverse innovation and opportunities for implementation science	Training opportunities for early-career investigators	Personal enrichment	U.S. Department of State: soft-power influence through health diplomacy
Unique environmental exposures and doses	Improve reputation and prestige and thus the strength of faculty and student applicants	Expanded pool of mentors	Industry: help feed pipeline of young investigators; efficiency of clinical trials; support labor force for U.S. industries abroad
Genetic diversity	Create sense of solidarity among faculty	Develop leadership skills	Global academic partners: universities working together to develop research infrastructure and skills
Immigrant and minority health	Engage in university mission	Establish partnerships that could last decades	Research investments can be sources of revenue through patentable ideas
U.S. military, expatriate, and traveler health	Increase visibility with other organizations	Platform for early-career investigators to develop their own pathways	-
Standardization and validation of different tools in diverse populations	Partnering with other strong institutions in low- and middle-income countries extends reach of limited resources	Interdisciplinary exchange of ideas, new perspectives, and persons	-
Access to diseases or advanced disease stages that are rare in the United States	Diversify student body, trainees, and faculty from low- and middle-income countries	-	-
Unique opportunity to study interactions with infectious diseases	Increase breadth of diseases studied and appeal to prospective students and faculty	-	-
Basic science research cheaper	Research drives creativity and innovation in health care	-	-
Drug discovery (traditional medicines)	-	-	-

SUPPORT EARLY-CAREER INVESTIGATORS AND MENTORS

Early-career investigators are the current front line and future leaders of global NCD research, but their career pathways are poorly defined. U.S. universities should adopt new metrics of success that reward public health effect and team science and recognize that, in today's globalized scientific community, an interdependent researcher is more valuable than an independent researcher.

The increasing difficulty in obtaining funding further complicates the pathway for early-career investigators. Although the NIH once funded 1 out of 3 research proposals, it now funds only 1 out of 6 (8). Career Development ("K") Awards, which are critical for early-career investigators, are extremely competitive, particularly for global NCD researchers. The funding pathways after "K" Awards are even more competitive, and investigators often rely on "R" Awards. An increase in funding devoted to global NCD research would be an important first step toward supporting talented scientists. Concurrently, universities could increase hard-money and exploratory grants to encourage these high-impact endeavors. Global NCD mentors also need financial support to dedicate time to training and building NCD research capacity at their universities and in partnering countries.

Several examples of success are worth noting. The National Heart, Lung, and Blood Institute Global Health Strategic Plan highlights the need for global translational research (9). It will be important for other NIH

institutes and centers as well as other governmental and nongovernmental funding agencies to emphasize global NCDs in their strategic plans. Investigators in the United States should seek opportunities to sit on NIH study sections to ensure that global NCD projects are reviewed and scored fairly, particularly in light of their large potential for public health effect. In this regard, the dramatic misalignment between the global burden of disease and U.S. funding agency priorities (far more resources are available for HIV and AIDS than for NCDs, which cause more deaths) must be addressed (10). Policymakers in the United States can lead the way to address NCDs as they did with the Global Fund for HIV/AIDS and the President's Emergency Plan for AIDS Relief.

CONCLUSION

Achieving these 4 action items requires complementary contributions by U.S. global NCD researchers, funders (both public and private), and universities. Increased collaboration across university-based centers focused on global NCDs is also essential. Finally, global NCD research must coincide with political efforts to address known NCD risk factors and disparities in health. Advocacy for each of these changes will be critical. The time for action is now.

From Rollins School of Public Health, Emory University, Atlanta, Georgia; Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, North Carolina;

School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; Brigham and Women's Hospital and Young Professionals Chronic Disease Network, Boston, Massachusetts; Vanderbilt Institute for Global Health, Vanderbilt University, Nashville, Tennessee; Yale School of Medicine, New Haven, Connecticut; University of North Carolina, Chapel Hill, North Carolina; Center for Global Health, Weill Cornell Medical College, New York, New York; and University of Washington, Seattle, Washington.

Acknowledgment: The authors thank Emory University, Office of the Provost, Rollins School of Public Health, Hubert Department of Global Health, and the Emory Global Diabetes Research Center; the Hubert-Yeargen Center for Global Health at Duke University; and the VECD (Vanderbilt, Emory, Cornell, Duke) Fogarty Global Health Fellowship Program (R25 TW009337) housed at the Vanderbilt Institute for Global Health for their financial contribution to the U.S. Investigators' Network Symposium on Global Non-Communicable Diseases Research, held in Atlanta, Georgia, on 8-9 September 2014.

For a list of participants in the U.S. Investigators' Network Symposium on Global Non-Communicable Diseases Research, see the **Appendix** (available at www.annals.org).

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-1068.

Requests for Single Reprints: Lindsay M. Jaacks, PhD, Rollins School of Public Health, Claudia Nance Rollins Building, 7040-I, 1518 Clifton Road, Atlanta, GA 30307; e-mail, ljaacks@emory.edu.

Current author addresses and author contributions are available at www.annals.org.

Ann Intern Med. 2015;163:712-714. doi:10.7326/M15-1068

References

1. Merson MH. University engagement in global health. *N Engl J Med.* 2014;370:1676-8. [PMID: 24785204] doi:10.1056/NEJMp1401124
2. Lamptey P, Dirks R. Building on the AIDS response to tackle non-communicable disease [Editorial]. *Glob Heart.* 2012;7:67-71. [PMID: 25691169] doi:10.1016/j.gheart.2012.01.010
3. Vermund SH, Narayan KM, Glass RI. Chronic diseases in HIV survivors [Editorial]. *Sci Transl Med.* 2014;6:241ed14. [PMID: 24944191] doi:10.1126/scitranslmed.3008684
4. Syed SB, Dadwal V, Martin G. Reverse innovation in global health systems: towards global innovation flow [Editorial]. *Global Health.* 2013;9:36. [PMID: 23992598] doi:10.1186/1744-8603-9-36
5. Thompson MJ, Huntington MK, Hunt DD, Pinsky LE, Brodie JJ. Educational effects of international health electives on U.S. and Canadian medical students and residents: a literature review. *Acad Med.* 2003;78:342-7. [PMID: 12634222]
6. Heimburger DC, Warner TL, Carothers CL, Blevins M, Thomas Y, Gardner P, et al. Recruiting post-doctoral fellows into global health research: selecting NIH Fogarty International Clinical Research Fellows. *Am J Trop Med Hyg.* 2014;91:219-24. [PMID: 24865678] doi:10.4269/ajtmh.13-0741
7. Varmus H. Building a global culture of science. *Lancet.* 2002;360 Suppl:s1-4. [PMID: 12504480]
8. Collins FS. Exceptional opportunities in medical science: a view from the National Institutes of Health. *JAMA.* 2015;313:131-2. [PMID: 25585318] doi:10.1001/jama.2014.16736
9. National Heart, Lung, and Blood Institute. NHLBI Global Health Strategic Plan, 2012-2017. Bethesda, MD: National Institutes of Health; 2012. NIH Publication 12-7857. Accessed at www.nhlbi.nih.gov/about/org/globalhealth/resources/OGHStrategicPlan%2007022012%20-%20FINAL.pdf on 29 July 2015.
10. Dieleman JL, Graves CM, Templin T, Johnson E, Baral R, Leach-Kemon K, et al. Global health development assistance remained steady in 2013 but did not align with recipients' disease burden. *Health Aff (Millwood).* 2014;33:878-86. [PMID: 24714869] doi:10.1377/hlthaff.2013.1432

Current Author Addresses: Dr. Jaacks: Rollins School of Public Health, Claudia Nance Rollins Building, 7040-I, 1518 Clifton Road, Atlanta, GA 30307.

Dr. Ali: Rollins School of Public Health, Claudia Nance Rollins Building, 7040, 1518 Clifton Road, Atlanta, GA 30307.

Drs. Bartlett and Bloomfield: Duke Global Health Institute, 310 Trent Drive, Durham, NC 27710.

Dr. Checkley: Johns Hopkins University, Suite 9121, 1800 Orleans Avenue, Baltimore, MD 21205.

Dr. Gaziano: Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115.

Dr. Heimbürger: Vanderbilt Institute for Global Health, 2525 West End Avenue, Nashville, TN 37212.

Dr. Kishore: Yale School of Medicine, 333 Cedar Street, New Haven, CT 06510.

Dr. Kohler: University of North Carolina Gillings School of Global Public Health, 135 Dauer Drive, 1101 McGavran-Greenberg Hall, Campus Box #7411, Chapel Hill, NC 27599.

Dr. Lipska: Yale School of Medicine, PO Box 208020, New Haven, CT 06520.

Ms. Manders: Rollins School of Public Health, Claudia Nance Rollins Building, 7040-L, 1518 Clifton Road, Atlanta, GA 30322.

Dr. Ngaruiya: Yale School of Medicine, 464 Congress Avenue, Suite 260, New Haven, CT 06519.

Dr. Peck: Weill Cornell Medical College Center for Global Health, 402 East 67th Street, 2nd Floor, New York, NY 10065.

Dr. Burroughs Pena: University of California, 505 Parnassus Street, 11th Floor, San Francisco, CA 94143.

Dr. Watkins: University of Washington, 325 9th Avenue, Box 359780, Seattle, WA 98104.

Dr. Siegel: Rollins School of Public Health, Claudia Nance Rollins Building, 7040-J, 1518 Clifton Road, Atlanta, GA 30322.

Dr. Venkat Narayan: Rollins School of Public Health, Claudia Nance Rollins Building, 7049, 1518 Clifton Road, Atlanta, GA 30322.

Author Contributions: Conception and design: L.M. Jaacks, M.K. Ali, J. Bartlett, G.S. Bloomfield, W. Checkley, T.A. Gaziano, D.C. Heimbürger, S.P. Kishore, R.E. Kohler, K.J. Lipska, O. Manders, C. Ngaruiya, R. Peck, M. Burroughs Pena, D.A. Watkins, K.R. Siegel, K.M. Venkat Narayan.

Analysis and interpretation of the data: L.M. Jaacks, K.M. Venkat Narayan.

Drafting of the article: L.M. Jaacks, K.M. Venkat Narayan.

Critical revision of the article for important intellectual content: L.M. Jaacks, M.K. Ali, J. Bartlett, G.S. Bloomfield, W. Checkley, T.A. Gaziano, D.C. Heimbürger, S.P. Kishore, R.E. Kohler, K.J. Lipska, O. Manders, C. Ngaruiya, R. Peck, M. Burroughs Pena, D.A. Watkins, K.R. Siegel, K.M. Venkat Narayan. Final approval of the article: L.M. Jaacks, M.K. Ali, J. Bartlett, G.S. Bloomfield, W. Checkley, T.A. Gaziano, D.C. Heimbürger, S.P. Kishore, R.E. Kohler, K.J. Lipska, O. Manders, C. Ngaruiya, R. Peck, M. Burroughs Pena, D.A. Watkins, K.R. Siegel, K.M. Venkat Narayan.

Obtaining of funding: J. Bartlett, D.C. Heimbürger, K.M. Venkat Narayan.

Administrative, technical, or logistic support: G.S. Bloomfield, O. Manders.

Collection and assembly of data: L.M. Jaacks, R.E. Kohler, C. Ngaruiya.

APPENDIX: PARTICIPANTS IN THE U.S. INVESTIGATORS' NETWORK SYMPOSIUM ON GLOBAL NON-COMMUNICABLE DISEASES RESEARCH

Participating institutes provided sponsorship for their junior and senior investigators to attend this event. Participants are listed alphabetically by affiliation. They provided perspectives and information, but the responsibility for writing and developing recommendations was that of the authors.

Abt Associates, Cambridge, Massachusetts
Pat Shifflett

American Cancer Society, Atlanta, Georgia
Farhad Islami

Brigham & Women's Hospital, Boston, Massachusetts
Thomas Gaziano

Case Western Reserve University, Cleveland, Ohio
Chris Longenecker

Centers for Disease Control and Prevention, Atlanta, Georgia
Michael Ballesteros
Naomi E. Chen
Andrea Neiman
Mona Saraiya

Doris Duke Charitable Foundation, New York, New York
Betsy Myers

Duke University, Durham, North Carolina
Anubha Agarwal
John Bartlett
Janet Prvu Bettger
Cynthia A. Binanay
Gerald Bloomfield
Melissa Burroughs Pena
Kelly Matthews Deal
Marlee Krieger
Laura Musselwhite
Neha J. Pagidipati
Uptal D. Patel
Devon Paul
John W. Stanifer
Nathan Thielman
Eric J. Velazquez

EDC Center for Diabetes Education, Atlanta, Georgia
Mahmoud Ibrahim

Emory University, Atlanta, Georgia
Mohammed Ali

Eeshwar K. Chandrasekar
Caroline V. Coburn
Solveig A. Cunningham
James W. Curran
Ralph J. DiClemente
Mary Foote
Nicole Ford
Karla Galaviz
Theresa W. Gillespie
Unjali Gujral
Danny Haddad
Lindsay M. Jaacks
R.L. Felipe Lobelo
Olivia Manders
Neil Mehta
K.M. Venkat Narayan
Shivani A. Patel
Martha Ryan
Nida Shaikh
Karen Siegel
Lisa Staimez
Parminder S. Suchdev
Mary Beth Weber

Georgetown University, Washington, DC
Emily Mendenhall

Georgia State University, Atlanta, Georgia
Matthew Magee

Harvard University, Boston, Massachusetts
Christina P.C. Borba
Andrea Feigl

Project HOPE, Health Affairs, Bethesda, Maryland
Jonathan Bor

Icahn School of Medicine at Mount Sinai, New York, New York
Rajesh Vedanthan

Johns Hopkins University, Baltimore, Maryland
William Checkley
Phabiola M. Herrera Aldana
Catherine H. Miele
Laura D. Sander
Sandra Zaeh

National Institutes of Health, Bethesda, Maryland
National Cancer Institute: John Flanigan
National Heart, Lung, and Blood Institute: Michael M. Engelgau
National Institute of Diabetes and Digestive and Kidney Diseases: Andrew A. Bremer
National Institute of Mental Health: Beverly Pringle

Northwestern University, Chicago, Illinois
Mark D. Huffman

Partners in Health, Boston, Massachusetts
Nancy Ferguson
Maia Olsen
Paul H. Park

Population Services International, Washington, DC
Heather White

Social & Scientific Systems, Silver Spring, Maryland
Yvette Delph
Andy Menke
Susan Sepelak

Stanford University, Stanford, California
Andrew Y. Chang

The Coca-Cola Company, Atlanta, Georgia
Rhona S. Applebaum

University of Alabama, Birmingham, Alabama
Amanda Willig

University of California, San Francisco, California
Dhruv S. Kazi
Jyoti Mishra

University of Michigan, Ann Arbor, Michigan
Justin List
Michele Heisler

University of North Carolina, Chapel Hill, North Carolina
Racquel Kohler
Rita K. Kuwahara
Elizabeth J. Mayer-Davis
Michelle A. Mendez
Christina Shay

University of Pittsburgh, Pennsylvania
Laurien Sibomana
Tushar Singh

University Research Co., Bethesda, Maryland
M. Rashad Massoud

University of South Carolina, Columbia, South Carolina
Nancy L. Fleischer

University of Southern California, Los Angeles, California
Mellissa Withers

University of Virginia School of Medicine, Charlottesville, Virginia
Ashley K. Volaric
Chris Winstead-Derlega

University of Washington, Seattle, Washington
Catherine P. Benziger

Manoj P. Menon
Deepa Rao
David Watkins

Vanderbilt University, Nashville, Tennessee

Catherine Lem Carothers
Douglas C. Heimbürger
Amina Merchant
Tecla M. Temu
Sten H. Vermund
Dana C.N. Walker

**Virginia Commonwealth University, Richmond,
Virginia**

Sudha Jayaraman

**Weill Cornell Medical College, New York, New
York**

Dan Fitzgerald

Robert Peck

Westat, Rockville, Maryland

Nancy L. Dianis
Laura Freimanis Hance
Jennifer Huang
Tracy L. Wolbach

Yale University, New Haven, Connecticut

Evelyn Hsieh
Kasia Lipska
Jeremy Schwartz
Sandeep Kishore
Christine Ngaruiya

**Young Professionals Chronic Disease Network,
Boston, Massachusetts**

Abigail Capobianco
Jordan D. Jarvis